Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Aggressive T Cell Hematological Malignancies
Part of paid clinical trials in Houston, Texas.
- Sponsor
- M.D. Anderson Cancer Center
- Study ID
- NCT07137481
- Phase
- PHASE2
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Hematological Malignancies
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 80 Years
- Healthy Volunteers
- Not accepted
Interventions
- C9/CD5CAR/IL-15 NK cells — DRUGGiven PO or IV
- Rituximab — DRUGGiven by IV
- Fludarabine — DRUGGiven by IV
- Cyclophosphamide — DRUGGiven by IV
Study Details
To determine the safety and efficacy (1-year PFS) of iC9/CD5CAR/IL-15 NK cells as consolidation in patients with aggressive T-cell malignances in first remission.
Key Dates
- Start date
- Feb 28, 2027
- Status verified
- Mar 2026
- Primary completion
- Jul 31, 2030
- Completion
- Jul 31, 2032
Study Design
- Enrollment
- 70 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Cohort 1 and Cohort 2: Treatment with Rituximab + iC9/CD5CAR/IL-15 NK CellsParticipants will recived treatment on an inpatient/outpatient basis at PI's discretion
Primary Outcome Measure
Safety and Adverse Events (AEs) [ Time Frame: Through study completion; an average of 1 year ]
Central Contacts
- Chitra Hosing, MD(713) 745-3219
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| The University of Texas M. D. Anderson Cancer Center | Houston | Texas | 77030 | Chitra Hosing, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Houston, TX
Related Studies
- Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical OutcomeRecruiting · Dana-Farber Cancer Institute · Boston, Massachusetts
- A Study of Talquetamab in Participants With Relapsed or Refractory Multiple MyelomaPHASE2 · Recruiting · Janssen Research & Development, LLC · Birmingham, Alabama
- Safety and Efficacy of SMART101 in Pediatric and Adult Patients With Hematological Malignancies After T Cell Depleted Allo-HSCTPHASE1/PHASE2 · Recruiting · Smart Immune SAS · New York, New York
- Long-term Follow-up of Participants Treated With Galapagos Chimeric Antigen Receptor (CAR) T-cell TherapiesPHASE3 · Recruiting · Lakefront Biotherapeutics NV · Boston, Massachusetts